BTT-T739-luc Orthotopic Mouse Model Service for Bladder Cancer

The BTT-T739-luc orthotopic mouse model unites the aggressive, metastasis-prone biology of a BBN-induced T739 bladder carcinoma with the optical traceability of stable firefly luciferase expression, enabling real-time quantification of primary tumor burden and visceral metastatic dissemination in a fully immunocompetent syngeneic host. Alfa Cytology engineers this luminescent platform with calibrated IVIS acquisition protocols, in vitro signal-validation checkpoints, and synchronized endpoint necropsy, delivering photon-flux datasets that correlate directly with ex vivo metastatic indices and histopathological grade.

Overview of BTT-T739-luc Orthotopic Mouse Model for Bladder Cancer

BTT-T739-luc is a genetically tagged derivative of the parental BTT-T739 murine bladder transitional cell carcinoma line, generated through stable integration of a firefly luciferase reporter—most frequently via lentiviral transduction or plasmid-based transfection followed by antibiotic selection. The engineered cells preserve the full tumorigenic repertoire of the BBN-induced parent, including poorly differentiated muscle-invasive histology, rapid detrusor invasion, and spontaneous visceral metastatic potential. When implanted orthotopically into the bladder lumen of syngeneic T739 mice following controlled mechanical mucosal injury, BTT-T739-luc cells achieve a 100% tumor take rate and emit a robust, ATP-dependent bioluminescent signal that is detectable within the first week of engraftment. This optical readout circumvents the subjectivity of palpation-based staging and permits longitudinal tracking of tumor expansion, response kinetics, and early metastatic seeding to the liver, kidney, mesentery, and peritoneum.

Fig 1. Bioluminescence imaging (BLI) method in an intravesical murine model. (Relouw, Sydney, et al., 2023)

The luciferase reporter adds a critical dimension to the model's established pro-angiogenic molecular signature, which is characterized by pronounced expression of VEGF-A, VEGF-C, and VEGFR-3. Researchers can now correlate quantitative photon-flux trajectories with vascular density changes, permeability shifts, and lymphangiogenic remodeling during anti-angiogenic therapy. Furthermore, the T739 syngeneic background maintains intact innate and adaptive immune compartments, allowing the model to serve as a dual-purpose platform for evaluating both vascular-targeting agents and immunomodulatory strategies in an anatomically faithful bladder microenvironment where tumor-immune-vascular crosstalk is preserved.

Cell Line Information: BTT-T739-luc

BTT-T739-luc inherits the aggressive biological behavior and pro-angiogenic profile of its parental line while adding a quantifiable optical reporter for non-invasive tumor monitoring. The table below summarizes its construction, phenotypic properties, and imaging parameters.

Our Services

Alfa Cytology orchestrates BTT-T739-luc orthotopic studies through an integrated pipeline that spans in vitro luciferase-expression QC, drift-angle stylet surgical implantation, locked-parameter IVIS imaging, and terminal ex vivo photon-flux corroboration. Our scientists calibrate D-luciferin dosing schedules, region-of-interest drawing protocols, and background-subtraction algorithms to your specific analytical needs, ensuring that every photon-flux curve is anchored by rigorous histopathology and immune-profiling data.

Workflow of BTT-T739-luc Orthotopic Mouse Model Construction

Construction of the BTT-T739-luc orthotopic model demands meticulous coordination between reporter-cell qualification, mechanical mucosal preconditioning, and standardized bioluminescence acquisition to achieve both high tumor take rates and quantifiable optical readouts. The workflow below delineates each critical phase from cell validation through longitudinal imaging to terminal metastasis survey.

1. Luciferase Expression Validation and Cell Preparation: BTT-T739-luc cells are expanded under antibiotic selection pressure to maintain reporter stability. An in vitro Bright-Glo or equivalent luciferase assay is performed 24 hours prior to implantation to confirm homogeneous, high-level bioluminescence across the population. Only cultures with >90% viability (trypan blue exclusion) and a consistent signal-to-background ratio exceeding 1×10⁴ relative light units (RLU) per cell are qualified. Cells are washed twice in PBS to remove serum and resuspended at 1×10⁸ cells/mL in sterile PBS, then maintained on ice.
2. Animal Preparation and Anesthesia: Female T739 mice, 4–6 weeks old and weighing 20–22 g, are acclimatized for a minimum of one week under SPF barrier conditions. On the procedure day, general anesthesia is induced via intraperitoneal sodium pentobarbital (60 mg/kg). Depth of anesthesia is confirmed by absence of the toe-pinch reflex. Ophthalmic ointment is applied, and the mouse is positioned supine on a thermostatically controlled surgical surface.
3. Mechanical Mucosal Preconditioning: A 24-gauge venous retention needle casing, lubricated with liquid paraffin, is inserted transurethrally into the bladder lumen. Residual urine is evacuated by gentle suprapubic compression. The stylet—pre-bent at a 5° to 7° angle approximately 15 mm from the tip to create a rotation radius of 2.61–3.66 mm—is advanced through the casing and rotated five full turns to disrupt the urothelial barrier. The stylet is withdrawn, leaving the casing in place for cell delivery.
4. Intravescial BTT-T739-luc Instillation: The validated cell suspension (100 µL containing approximately 1×10⁷ cells) is injected immediately through the indwelling casing into the bladder lumen. The casing is then withdrawn, and the mouse is maintained supine for several minutes to promote cell-mucosal adhesion. No external clamping is required given the retention dynamics of the mechanically injured bladder wall.
5. Post-Instillation Recovery and Baseline Imaging: Mice are placed in warmed recovery cages and monitored for return of righting reflex. Body weight, activity, hydration, and hematuria are recorded daily for 72 hours. At 48–72 hours post-implantation, a baseline bioluminescence image may be acquired to confirm successful cell seeding, although robust primary-tumor signal typically emerges by day 5–7.
6. Longitudinal Bioluminescence Imaging and Metastasis Surveillance: Tumor growth and metastatic spread are monitored via serial IVIS imaging performed twice weekly. Mice receive intraperitoneal D-luciferin (150 µg/g body weight) and are imaged under isoflurane anesthesia 10–15 minutes post-injection. Acquisition parameters (exposure time, binning, f/stop) are locked across all sessions. ROIs are drawn over the bladder and thoracoabdominal cavity; total photon flux (photons/second) is quantified per region. A >2-fold increase in extra-vesical photon flux prompts focused ex vivo imaging of suspected metastatic organs at necropsy.
7. Terminal Necropsy, Ex Vivo Imaging, and Tissue Collection: At humane endpoint or protocol-defined timepoints, a final whole-body bioluminescence image is acquired to document metastatic dissemination. Mice are euthanized, and the bladder is excised, weighed, and photographed. Systematic metastasis survey is conducted across the liver, kidneys, mesentery, peritoneum, lungs, and spleen. Each organ is imaged ex vivo for photon-flux confirmation. Tissues are partitioned for formalin-fixed paraffin-embedded (FFPE) histopathology, snap-frozen molecular extraction, and flow-cytometric immune profiling. Ex vivo luciferase assays on tissue homogenates corroborate in vivo imaging data.

Case Study-BTT-T739-luc Orthotopic Mouse Model Development

In a preclinical engagement focused on anti-angiogenic combination therapy, Alfa Cytology established a BTT-T739-luc orthotopic cohort to evaluate a novel small-molecule VEGFR-3 inhibitor administered intravesically in conjunction with systemic anti-PD-L1 blockade. Following mechanical mucosal preconditioning and intravesical instillation, bioluminescence imaging confirmed uniform primary tumor engraftment across all study animals by day 6, with photon flux increasing logarithmically through day 20. The experimental design incorporated an intravesical BCG comparator arm, a VEGFR-3 inhibitor monotherapy arm, and a combination arm. Serial imaging revealed divergence in bladder photon-flux trajectories between monotherapy and combination groups by day 14, while whole-body scans at day 21 detected extra-vesical signal in 25% of control animals versus 8% of combination-treated animals. Terminal analyses correlated reduced photon flux with diminished CD31⁺ microvessel density and lower VEGF-C immunohistochemical staining intensity, yielding pharmacodynamic evidence that informed the sponsor's subsequent formulation-optimization and dose-scheduling strategy.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for BTT-T739-luc orthotopic studies provides a preclinical environment where optical traceability, aggressive tumor biology, and comprehensive endpoint analytics are unified to accelerate your therapeutic discovery timeline.

• Expertise in drift-angle stylet mechanical preconditioning ensures reproducible 100% tumor take rates and consistent mucosal injury depth across T739 cohorts.
• In-house luciferase-expression QC and signal-stability monitoring guarantee that every implanted cohort begins with validated, high-fidelity reporter cells.
• Locked-parameter IVIS imaging with standardized D-luciferin dosing and ROI-based photon-flux quantification delivers statistically robust longitudinal data across treatment arms.
• The model's documented ~23% visceral metastatic rate, combined with whole-body bioluminescence surveillance, enables preclinical evaluation of anti-metastatic agents and adjuvant therapies with early detection capability.
• Integrated VEGF-pathway analytics—including IHC, ELISA, and transcriptomic quantification—are aligned with the line's pro-angiogenic molecular signature for mechanism-of-action studies.
• All studies are conducted within SPF barrier facilities under IACUC-approved protocols, with comprehensive necropsy documentation, ex vivo imaging corroboration, and GLP-compatible data packages available.

Contact Us

If your bladder cancer discovery program requires an aggressive, metastasis-capable orthotopic model with real-time bioluminescence tracking and proven syngeneic fidelity, reach out to Alfa Cytology to discuss how our BTT-T739-luc platform can advance your therapeutic candidates. Our scientific team will design a customized imaging study, calibrate endpoint matrices to your compound's mechanism of action, and provide a detailed project proposal. Contact us today to initiate a conversation that bridges optical preclinical data with translational readiness.

For research use only. Not intended for any clinical use.